Treatment and survival analyses of malignant mesothelioma in Japan

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 803-808

  Gemba, Kenichi ^a,e   Fujimoto, Nobukazu ^a   Aoe, Keisuke ^b   Kato, Katsuya ^c   Takeshima, Yukio ^d   Inai, Kouki ^d   Kishimoto, Takumi ^a  

^a OKAYAMA ROSAI HOSPITAL   (Japan)

^b NATIONAL SANYO HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; EPITHELIOID SARCOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MONOTHERAPY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SARCOMATOID CARCINOMA; TREATMENT DURATION; HISTOLOGY; HUMAN TISSUE; JAPAN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84875939728     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.709948     Document Type: Article

References (17)

1. Wagner JC, S leggs CA, M archand P. D iffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-71.
2. Muers MF, S tephens RJ, F isher P, D arlison L, H iggs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 2008; 371: 1685-94.
3. Sugarbaker DJ, Flores RM, J aklitsch MT, R ichards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999; 117: 54-63, Discussion 63-5.
4. Spirtas R, C onnelly RR, Tucker MA. S urvival patterns for malignant mesothelioma: The SEER experience. Int J Cancer 1988; 41: 525-30.
5. Gemba K, Fujimoto N, K ato K, A oe K, T akeshima Y, Inai K, et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 2012; 103: 483-90.
6. Churg A, Inai K, Samet J. Tumours of the pleura. Lyon: IARC Press; 2004.
7. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8.
8. Herndon JE, G reen MR, C hahinian AP, C orson JM, S uzuki Y, Vogelzang NJ. Factors predictive of survivaLamong 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-31.
9. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of CanceRexperience. J Clin Oncol 1998; 16: 145-52.
10. Fennell DA, Parmar A, S hamash J, E vans M T, S heaff M T, Sylvester R, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005; 23: 184-9.
11. Treasure T, T an C, Lang-Lazdunski L, W aller D. The MARS trial: Mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006; 5: 58-9.
12. Treasure T, Lang-Lazdunski L, W aller D, B liss JM, T an C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12: 763-72.
13. Kushitani K, T akeshima Y, A matya VJ, F uronaka O, Sakatani A, Inai K. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int 2008; 58: 75-83.
14. Walters J, M askell NA. B iopsy techniques for the diagnosis of mesothelioma. Recent Results Cancer Res 2011; 189: 45-55.
15. Kalmadi S R, Rankin C, Kraut MJ, JacobSaD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60: 259-63.
16. Vogelzang NJ, R usthoven JJ, S ymanowski J, Denham C, Kaukel E, Ruffi e P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
17. Nakagawa K, Y amazaki K, K unitoh H, H ida T, G emba K, Shinkai T, et al. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: A phase I/II study in Japanese patients. Jpn J Clin Oncol 2008; 38: 339-46.